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Botulinum neurotoxin serotype A (BoNT/A) is the most potent poison of biological origin
known to mankind. The toxicity of BoNT/A is due to the inhibition of neurotransmission at
cholinergic synapses; this is responsible for the symptom of ﬂaccid paralysis at peripheral
neuromuscular junctions. At a molecular level, the BoNT/A effect is due to its inhibition of
stimulated acetylcholine (ACh) release from presynaptic nerve terminals. Currently, there
is no antidote available to rescue BoNT/A-poisoned synapses. Here, we report an example
of rescuing botulinum-poisoned cultured mouse spinal cord neurons by treatment with
Mastoparan-7 (Mas-7), which is known to be a phospholipase A2 activator compound.
Mas-7, a naturally occurring bee venom peptide, was delivered to botulinum-poisoned
neurons via a drug delivery vehicle (DDV) construct prepared using the recombinant
non-toxic heavy chain (HC) fragment of BoNT/A itself. In this method, the BoNT/A HC
component in the DDV served as a neuron speciﬁc drug targeting molecule. We found that
Mas-7 delivered into BoNT/A intoxicated spinal cord cells restored over 40% their property
of stimulated neurotransmitter release. Rescue from cell poisoning did not occur from
inhibition of the endopeptidase activity of BoNT/A light chain (LC) against its well-known
substrate, SNAP-25 that is mechanistically involved in the cholinergic neuroexocytosis
process. Rather, Mas-7 induced a physiological host response apparently unrelated to
SNAP-25, but linked to the phospholipase-mediated signal transduction pathway.
Published by Elsevier Ltd.1. Introduction
Botulinum neurotoxins (BoNTs) are produced by the
anaerobic bacterial species, Clostridium botulinum and are
the cause of botulism, a life-threatening neuroparalytic
disease. BoNTs cause neuroparalysis by blocking neuro-
transmitter release from presynaptic neurons at the
neuromuscular junctions. Among the seven serotypes ofC-ND license (http://
x: þ1 301 319 9449.
hati.ray@us.army.mil
er Ltd.BoNTs, designated A to G, the BoNT/A serotype is the most
toxic with its potency at a picomolar (pM) concentration.
BoNT/A is a dichain peptide consisting of about a 100-kDa
heavy chain (HC) and a 50-kDa light chain (LC). Each of
these two peptide components serves its speciﬁc function
in the mechanism of BoNT/A action. The sequential steps in
the mechanism consist of (a) toxin internalization into
neurons via speciﬁc receptor binding by the HC followed by
vesicular endocytosis of the holotoxin; (b) separation of the
LC from the HC inside a lower pH environment of the
endosomes via the cleavage of the disulﬁde linkage be-
tween the HC and LC; (c) formation by the HCs of endo-
somal membrane pores, which serve as conduits for the
release of the LCs into the cytosol; and ﬁnally, (d) an
endopeptidase function of the LC in the neuronal cytosol
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tein called synaptosomal-associated membrane protein
(SNAP-25) and, thus, inhibiting the Ca2þ-dependent
stimulus-induced release of neurotransmitter molecules
e.g., acetylcholine from presynaptic neurons. Attempts to
develop BoNT/A countermeasures have mostly focused on
inhibiting one or more of these steps. However, our pre-
vious reports (Ray et al., 1993,1999; Ishida et al., 2004) have
indicated that besides the BoNT/A LC-induced SNAP-25
hydrolysis mechanism described above, there could be an
alternate mechanism of inhibition of neuroexocytosis by
BoNT/A. We had proposed that this alternate mechanism
involves BoNT/A effects on the roles of PLA2, arachidonic
acid (AA), lysophosphatidic acid (LPA) and RhoB in stimu-
lated neuroexocytosis. We had also demonstrated that in
nerve growth factor-differentiated PC-12 cells, Mas plus
high (80 mM) Kþ caused ACh release in an apparently
SNAP-25 independent manner (Ray et al., 1997). These
observations, taken together, would suggest the PLA2-
dependent mechanisms of neuroexocytosis as an alternate
therapeutic target for botulinum intoxication. In this
report, we provide a proof of this concept by showing that a
potent PLA2 activator, Mas-7 can rescue BoNT/A-poisoned
cultured spinal cord neurons by restoring their stimulus-
induced neurotransmitter release function.
BoNTs are extremely potent food poisons, with a mouse
LD50 of 0.1 ng/kg for BoNT/A (Greenﬁeld et al., 2002; Arnon
et al., 2001). Contamination of restaurant, catered or com-
mercial foodstuffs or beverages could cause illness in a
large number of consumers (Greenﬁeld et al., 2002).
Aerosol exposure of BoNTs does not occur naturally, but
could be attempted by bioterrorists to achieve a wide-
spread effect. It has been estimated that a single gram of
crystalline toxin, evenly dispersed and inhaled, could kill
more than one million people (Arnon et al., 2001). There-
fore, developing a pharmacological countermeasure that
will be effective in rescuing the BoNT/A poisoned nerve
cells from their impaired cholinergic functions is an urgent
priority for treatment BoNT/A-exposed victims.
The Current therapy for botulism involves respiratory
supportive care and the administration of antitoxin. The
only antitoxins available are equine antitoxin. However,
equine antitoxin can only target the toxins at extracellular
level, and cannot reverse the paralysis caused by botu-
lism. In addition, equine antibody can cause severe hy-
persensitivity reactions, and is limited to be used for
prophylactic treatment (Cai and Singh, 2007). An inves-
tigational heptavalent antitoxin BabyBIG (against sero-
types A, B, C, D, E, F and G), derived from the blood of
human donors vaccinated with a pentavalent (ABCDE)
toxoid vaccine, is only available for infant botulism
(Francisco and Arnon, 2007). However, an antitoxin must
be administered before toxins reach the nerve cells;
moreover, the therapeutic window for using an antitoxin
is short. Once the toxic syndrome is developed, the
antitoxin is less effective since the antitoxin cannot get
into the nerve cell to neutralize the toxin.
The ﬂaccid muscle paralysis caused by BoNT/A lasts for
several months (Cherington,1998). Therefore, patients who
have already developed the syndrome have to be put under
respiratory intensive care for this long duration of paralysis(Greenﬁeld et al., 2002; Arnon et al., 2001; Rosenbloom
et al., 2002). The estimated cost for each botulism patient
under respiratory supportive care could be as high as US
$350,000 (Wein and Liu, 2005). This puts a large burden on
hospitals, both ﬁnancially and in resource management.
Should a bioterrorist attack occur, there will be a public
health crisis due to the lack of effective antidotes against
botulism, especially in the absence of a reliable presymp-
tomatic diagnosis. Mass immunization is neither feasible
nor desirable, primarily because BoNT is an effective ther-
apeutic agent against numerous neuromuscular disorders
and also has a wide range of cosmetic applications
(Eubanks and Dickerson, 2007). An effective medical
countermeasure strategy would require developing a drug
that could rescue poisoned neuromuscular synapses and
include its efﬁcient delivery speciﬁcally to poisoned pre-
synaptic nerve terminals. We reported that mastoparan
(Mas), a bee venom PLA2 activator, stimulates neurotrans-
mitter release in BoNT/A treated PC12 cells (Ray et al., 1997,
1999). In these studies, we had observed that Mas-7, a more
potent (PLA2 activity) isomer of Mas (Konrad et al., 1995)
was also more potent in stimulating neurotransmitter
release; whereas, an inactive isomer mastoparan-17 (Mas-
17) was without any effect (Ross and Higashijima, 1994).
These observations led to the belief that Mas could serve as
a prospective pharmacological antagonist of botulinum
poisoning. Recently, we developed a drug delivery strategy
that could deliver toxin antidotes directly into the intoxi-
cated nerve terminal cytosol (Zhang et al., 2009). The re-
sults presented in this report demonstrate the effectiveness
of a drug delivery strategy using Mas-7, a BoNT/A antago-
nist, into the intoxicated nerve terminal cytosol accompa-
nied by a protective response against BoNT/A.2. Materials and methods
2.1. Spinal cord cultures
Timed pregnant C57BL/6NCR mice were obtained from
the Frederick Cancer Research and Development Center
(Frederick, MD). The experimental protocol was approved
by the Animal Care and Use Committee at Walter Reed
Army Institute of Research and all procedures were con-
ducted in accordance with the principles stated in the
Guide for the Care and Use of Laboratory Animals and the
Animal Welfare Act of 1966 (P.L. 89–544), as amended.
Fetal mice at gestation day 13 were euthanized in a
chamber ﬁlled with CO2 gas followed by cervical disloca-
tion and their embryos harvested for collection of the spi-
nal cord. Spinal cords were removed from embryos. Cells
were dissociated with trypsin and plated in collagen-
coated 4 well coverslips or 35 mm diameter 6-well cul-
ture plates at a density of 105 cells/cm2 (Zhang et al., 2009).
Cells were grown in Eagle’s Minimum Essential Medium
with 5% heat-inactivated horse serum and a nutrient sup-
plement (N3) at 37 C in 90% air/10% CO2. Cell cultures were
treated with 54 mM 5-ﬂuoro-2-deoxyuridine and 140 mM
uridine from day 5–9 after plating to inhibit glial prolifer-
ation. Cultures were fed 1–2 times per week and were used
for experiments at 1–3 weeks after plating.
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After 8 h incubation of primary cultured spinal cord cells
with 1pM of BoNT/A, 3[H]glycine release was determined
by a modiﬁcation of the method described by Zhang et al.
(2009). Spinal cord cells were incubated at 37 C for
30 min in HEPES-buffered saline (HBS) containing 2 mCi/ml
3[H]glycine to label the intracellular glycine pool. The cells
were washed three times with Ca2þ-free HBS and incu-
bated for 7 min in this modiﬁed HBS solution containing
5 mM KCl/0 mM Ca2þ, and then were stimulated for 7 min
with stimulation solution containing 2 mM Ca2þ and either
80 mM KCl alone or 80 mM KCl plus mastoparan or mas-
toparan analogs. Cells were washed again with the modi-
ﬁed HBS solution. All of solutions were adjusted to pH 7.4
and to 325  5 mosm/l. Each incubation solution was
collected, and the radioactivity was determined by scintil-
lation counting.
2.3. Construct a model drug conjugated drug delivery vehicle
A drug delivery vehicle (DDV) conjugated with the drug,
Mas-7 (DDV-Mas-7) was constructed as described (Zhang
et al., 2009). The DDV consisted of the following: a
neuronal targeting molecule, Cy3 labeled recombinant
BoNT/A rHC linked by a disulﬁde bond at Cys454 of rHC to a
drug carrier molecule, 10 kDa dextran. A diagrammatic
representation of the DDV conjugated with FITC labeled
Mas-7 is shown in Fig. 1. The DDV-Mas-7 construct was
soluble and stable under our experimental conditions i.e.,
in aqueous medium at 37 C.
2.4. Uptake of DDV-Mas-7 by spinal cord neurons and release
of Mas-7 molecule
Uptakeof DDV-Mas-7 by spinal cordneurons and release
of dextran-Mas-7 from DDV-Mas-7 were determined byFig. 1. Schematic representation of the DDV for transport of BoNT/A antagonists. T
antagonist, Mas-7. The PDPH linker is bound to one of four possible cysteine (C)
normally participates in the disulﬁde linkage with the BoNT/A light chain (LC). The d
In a functional DDV, multiple drug molecules may be attached to the prototype deconfocal microscopy. Cells were exposed to DDV-Mas-7
(100 nM) in growth medium at 37 C for 16 h, which was
the optimum time for the DDV uptake and separation
(Zhang et al., 2009). Cells were subsequently washed and
ﬁxed overnight with 2% paraformaldehyde. The coverslips
containing ﬁxed cells were mounted between a glass slide
and glass coverslip and ﬂuorescent images were viewed on
a Bio-Rad 2000 laser confocal microscope.2.5. Immunoblotting of SNAP-25
For SNAP-25 immunoblotting, cells in each well were
lysed in 1% SDS with 1 mM EDTA and 1 mM EGTA. The
slurry was transferred to 1.5-ml microcentrifuge tubes,
incubated in a 95 C water bath for 5 min to inactivate
proteases, and then stored at 80 C. Immediately prior to
use, samples were thawed, mixed with equal volumes of
Tris-Tricine sample buffer (Bio-Rad), heated at 95 C for
4 min, and then separated by SDS-polyacrylamide gel
electrophoresis. Equal quantities of protein were loaded
onto 4–12% acrylamide gels. Proteins were separated using
0.1 M Tris-Tricine, pH 8.3, and then transferred to poly-
vinylidene diﬂuoride membrane with a buffer containing
192mMglycine, 25mMTris, pH 8.3, and 12%methanol. The
membranes were soaked in 20 ml of 4% BSA in Tris-
buffered saline-Tween 20 (TBST) buffer for 1 h at RT and
next probed overnight with 2 ml of Goat anti-SNAP25 in
the same buffer. After three 20-min washes with TBST, the
membranes were exposed for 1 h to monkey anti-goat
antibodies conjugated with horseradish peroxidase in
10 ml of blocking buffer. After washing three times with
TBST, the membranes were developed with a chemilumi-
nescent reagent (ECL). Same membrane was used for
house-keeping protein analysis, i.e. after blotting with anti-
SNAP25, the membranes were next used for anti-b-actin
analysis. Scanned images of Western blots were produced
and analyzed utilizing Bio-Rad quantity-one software.he schematic representation of the DDV construct conjugated with BoNT/A
sulfhydryl groups on the BoNT/A rHC. It is shown attached to C454, which
extran is conjugated to the rHC by a C–N bond in one of the glucose residues.
xtran carrier.
P. Zhang et al. / Toxicon 76 (2013) 37–43403. Results
3.1. Mastoparans mitigate the toxicity of BoNT/A in spinal
cord neurons model
To determine whether Mas affects glycine exocytosis,
3[H]glycine release was measured in the same cell prep-
arations of three-week old mouse spinal cord neuronal
cultures to examine a correlation between different
mastoparans and 3[H]glycine exocytosis (Fig. 2). Stimula-
tion with KCl (80 mM) released 3[H]glycine from un-
treated control cells, but the release was almost
completely prevented (only 2% of untreated control) from
BoNT/A (1 pM) poisoned cells. In these BoNT/A-treated
cells, Mas (10 mM) or Mas-7 (10 mM) alone released
about 30% and 50%, respectively, of the releasable pool of
3[H]glycine following 80 mM Kþ stimulation. A combi-
nation of Mas plus 80 mM Kþ increased 3[H]glycine
release from BoNT/A treated cells about one and half-fold
compared to that seen in untreated control cells (no
BoNT/A); the release was even higher (two-fold over un-
treated control) with Mas-7 plus 80 mM Kþ. On the other
hand, the inactive isomer, Mas-17 caused no stimulation
of 3[H]glycine release from BoNT/A treated cells with or
without 80 mM Kþ. These results suggested that either
Mas or Mas-7 could rescue cultured spinal cord neurons
from BoNT/A poisoning; however, Mas-7 was more potent
than Mas. Therefore, Mas-7 was chosen as the drug to
construct the drug conjugated DDV.Fig. 2. Glycine exocytosis due to mastoparans/KCl occurs in cultured mouse
spinal cord cells. 3[H]glycine release was measured as described in the
Materials and Methods section. Values (mean  sd of data from 3 to 6
separate experiments) are expressed as percent of 80 mM Kþ-stimulated
untreated (i.e, no toxin treatment) control (considered as 100%). 1) 80 mM
Kþ-stimulated untreated (no toxin) control, 2) 80 mM Kþ-stimulated cells
treated with BoNT/A (1 pM), 3) Mas alone (10 mM)-stimulated cells treated
with BoNT/A (1 pM), 4) Mas-7 alone (10 mM)-stimulated cells treated with
BoNT/A (1 pM), 5) Mas-17 alone (10 mM)-stimulated cells treated with BoNT/
A (1 pM), 6) Mas plus 80 mM Kþ-stimulated cells treated with BoNT/A
(1 pM), 7) Mas-7 plus 80 mM Kþ-stimulated cells treated with BoNT/A
(1 pM), 8) Mas-17 plus 80 mM Kþ-stimulated cells treated with BoNT/A
(1 pM).3.2. Mas-7 molecule could be separated from DDV-Mas-7 and
delivered into cytoplasm of spinal cord neurons
To test the efﬁcacy of drug delivery into neuronal
cytosol via the DDV, we monitored the separation of the
drug carrier-Mas-7 from the DDV-Mas7 construct by
confocal microscopy. Spinal cord neurons were treated for
16 h at 37 C with 100 nM ﬂuorescently labeled DDV-Mas-7
conjugate (Cy3 labeled rHC (red ﬂuorescence) conjugated
to FITC labeled Mas-7-dextran (green ﬂuorescence) shown
in Fig. 1.
The experimental design was to mimic a therapeutic
application of the DDV strategy to treat individuals
poisoned with BoNT/A and exhibiting clinical symptoms of
botulism. Since the targeted DDV approach is based on the
premise of a selective entry of DDV into presynaptic nerve
terminals via BoNT/A receptor mediated endocytosis, we
had demonstrated that the uptake of the DDV was via
BoNT/A receptors in our previous study (Zhang et al., 2009).
The confocal microscopy was used to detect the separation
of the DDV components. Spinal cord neurons were treated
for 16 h with 100 nM labeled DDV-Mas-7 conjugate
molecule at 37 C. The staining pattern of each dye was
extranuclear. The punctate nature of the staining suggested
clustering of DDV in vesicles. The staining of unseparated
DDV-Mas-7 was orange (red plus green labeling). The im-
ages shown in Fig. 3C highlight the presence of released
drug carrier (dextran)-Mas-7 component (green) in the
particles present in the nerve terminal cytosol. It indicated
that the separation of the drug carrier-Mas-7 fromDDVwas
in a fashion similar to the dissociation of the LC from the
internalized holotoxin in the endosomes as described
earlier under Introduction.
3.3. Mas-7 molecule delivered via the DDV into spinal cord
neurons could rescue BoNT/A poisoning
The goal of this study was to demonstrate that the
prospective botulinum antidote, Mas-7 delivered via the
DDV into neurons would be effective in rescuing the
stimulus-induced neurotransmitter release function from
its inhibition due to BoNT/A poisoning. The following were
the experimental approach and results to accomplish this
goal. Three-week old mouse spinal cord neuronal cultures
were treated with 1 pM BoNT/A at 37 C for 8 h. After
washing to remove excess toxin, cells were treated with
100 nM DDV-Mas-7 for 16 h at 37 C. High Kþ (80 mM)
stimulated [3H]glycine release vis-a-vis SNAP-25 hydrolysis
was examined under the different experimental conditions
used in these cells. The results showed that vesicular
neurotransmitter release, measured by the 80 mM Kþ-
evoked [3H]glycine release assay, was almost completely
inhibited in BoNT/A treated cells. Incubation of these BoNT/
A poisoned cells with DDV-Mas-7 substantially restored
(40% of normal cell control) the stimulated neurotrans-
mitter release function. (Fig. 4A). Interestingly, there was
only a partial cleavage of SNAP-25 (28% of total SNAP-25
protein) in neurons treated with 1 pM BoNT/A, a concen-
tration that almost completely blocked the 80 mM Kþ
stimulated [3H]glycine release (Fig. 4B). Moreover, there
was no signiﬁcant difference in the extent of SNAP-25
Fig. 3. The drug carrier molecule in DDV separates and translocates into neuronal cytosol. Three-week old spinal cord cultures were incubated for 16 h with
100 nM solutions of ﬂuorescently labeled DDV-Mas-7. Confocal images shown are as follows: A, Cy3 (red)-rHC: ﬂuorescence elicited at an excitation wavelength
of 543 nm; B, FITC (green)-Mas-7-dextran: ﬂuorescence elicited at an excitation wavelength of 488 nm; C, overlay of red and green showing either co-localization
(orange) or separation of rHC and dextran-Mas-7. Micrographs were obtained on a Bio-Rad 2000 laser confocal microscope using a 100  oil immersion objective.
Bars: 20 nm. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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with DDV-Mas-7 treatment. These ﬁndings suggested that
SNAP-25 cleavage may not necessarily be correlated with
the inhibition of neurotransmitter release due to BoNT/A.
Alternatively, factors other than SNAP-25 hydrolysis might
be responsible for BoNT/A inhibition of stimulated neuro-
transmitter release and its rescue by a pharmacological
agent such as Mas-7.S
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approach utilizing the BoNT/A rHC as a neuron speciﬁc
targeting molecule conjugated via a disulﬁde linkage to a
drug delivery platform (10 kD dextran) (Zhang et al., 2009).
Therapeutic targeting is important for two main reasons:
(a) minimizing systemic toxicity, if any, due to treatment
compounds, and (b) delivering an effective high concen-
tration of a therapeutic compound to the site of toxicity,
e.g., nerve terminals for botulism. We had demonstrated
that the targeting component of the DDV, i.e., rHC was
nontoxic (Zhang et al., 2009).
Glycine is a major inhibitory neurotransmitter in the
mammalian spinal cord where, by acting at strychnine-
sensitive receptors, it plays important roles in a variety of
motor and sensory functions. Within the spinal cord,
glycine can be released from nerve endings of glycinergic
neurons as well as from nerve terminals of interneurons in
which glycine and GABA are co-stored in the same vesicles
and from which the two amino acid transmitters are co-
released onto motoneurons (Chaudhry et al., 1998;
Jonas et al., 1998). In addition to the inhibitory functions,
glycine is involved in excitatory neurotransmission
(Supplisson and Roux, 2002). Therefore, glycine is an
important neurotransmitter in the spinal cord. 3[H]-glycine
release assay was initially used as an indicator of spinal
cord function for evaluation of Tetanus toxin (Williamson
et al., 1992) and botulinum neurotoxin (Williamson et al.,
1996). In this assay, 3[H]-glycine was taken up by cells in
physiological solution and released by depolarization with
56 mM Kþ in the presence of 2 mM Ca2þ. Since the assay is
relatively simple and reliable, it is accepted by researchers
in Clostridial neurotoxins studies.
In the present study, the objective was to test the utility
of a DDV-Mas-7 construct as a viable therapeutic against
botulism in a peripheral neuronal model. First, we observed
that in 3-week old cultured mouse embryonic spinal cord
neurons poisoned with 1 pM BoNT/A, Mas or Mas-7 alone
or in conjunction with high (80 mM) Kþ were able to
induce neurotransmitter ([3H]glycine) release; high Kþ
alone, Mas-17 alone or Mas-17 plus high (80 mM) Kþ were
ineffective (Fig. 2). Here, we have provided the evidence of
the following: 1) drug conjugated DDV can be effectively
taken up in targeted neurons via endocytosis, 2) the DDV-
drug conjugate components can be adequately separated
for drug delivery and diffused into the neuronal cytosol,
and 3) DDV-Mas-7 can serve as a functional antidote
against botulism. To our knowledge, this is the ﬁrst
experimental demonstration of a prospective therapeutic
approach to treat botulism in a relevant peripheral
neuronal model combined with a feasible targeted drug
delivery technology.
As described earlier, a widely accepted molecular
explanation of the mechanism of action of BoNT/A is that
its toxicity is due to its zinc-dependent endopeptidase ac-
tivity via proteolysis of SNAP-25, an essential component of
the exocytotic SNARE complex. Interestingly, the results
presented here showed that the Mas-7 rescue of neurons
from BoNT/A intoxication was not concordant with either
retaining or restoring the integrity of SNAP-25. It is note-
worthy that in BoNT/A poisoned neurons, DDV-Mas-7
treatment had no effect on SNAP-25 cleavage, suggestingthat Mas-7 in DDV was effective in rescuing neurons from
BoNT/A toxicity via a pathway that is independent of SNAP-
25. It was also reported that a dose–response data with
BoNT/A produced non-overlapping curves for SNAP-25
proteolysis and blockade of neurotransmitter release
(Keller and Neale, 2001). An alternative mechanism,
although not mutually exclusive, is that BoNT/A toxicity is
via a phospholipase A2 (PLA2)-dependent action involving
LPA and Rho-GTPase (RhoB) in the stimulus-induced
neurotransmitter release process (Ray et al., 1993, 1997,
1999; Ishida et al., 2004). According to this mechanism, a
stimulus-induced increase in intraterminal free Ca2þ con-
centration ([Ca2þ]i) activates PLA2, which causes arach-
idonic acid (AA) release frommembrane phospholipids. AA
has been proposed to act as a fusogen in the vesicle fusion
process. Lysophosphatidic acid (LPA), the other product of
PLA2 action, acts via LPA receptors to stimulate Rho-GTPase
(Rho-B), which regulates actin cytoskeletal organization.
Actin disorganization has been proposed to be a prerequi-
site for intraterminal vesicle migration and exocytosis. Our
results have shown that in PC12 cells, BoNT/A inhibits
neuroexocytosis by interfering with both PLA2-mediated
AA release (Ray et al., 1993, 1997, 1999) and RhoB-mediated
actin disorganization (Ishida et al., 2004). Our observation
of Mas-7 based rescue of BoNT/A-poisoned neuronal cells is
likely to engage this pathway of neurotransmitter release.
5. Conclusion
This study demonstrated a therapeutic approach to treat
botulismwith a feasible targeted drug delivery technology.
This report provides new knowledge of endocytosis and
exocytosis, as well as of BoNT trafﬁcking and action. In
particular, the results showing the efﬁcacy of DDV-Mas-7 in
rescuing neurons from botulism is consistent with our
previous reports on a PLA2- and RhoB-mediated mecha-
nism of BoNT/A toxicity. In addition, these results suggest
an alternative approach towards botulism intervention
other than the one commonly emphasized, i.e., protection
of vesicle fusion proteins, e.g., SNAP-25 for BoNT/A.
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